- Halozyme has raised its full-year 2025 adjusted EPS forecast to a range of $5.30 to $5.70, up from the previous $4.95 to $5.35. Analysts had estimated $4.90.
- The company anticipates 2025 revenue to be between $1.20 billion and $1.28 billion, which is an increase from the earlier estimate of $1.15 billion to $1.23 billion.
- First quarter results show an EPS of 93 cents and revenue of $264.9 million, surpassing the estimated $233.6 million.
- Adjusted EPS for the first quarter is $1.11, higher than the projected 82 cents.
- Research and development expenses came in lower than expected at $14.8 million, compared to the estimate of $21 million.
- The company’s cash and cash equivalents stood at $176.3 million, exceeding the estimate of $109.7 million.
- Operating income reached $141.5 million, beating the forecasted $119.9 million.
- Halozyme is raising its 2025 financial guidance, predicting YOY growth of 18% – 26% in total revenue, 25% – 33% in adjusted EBITDA, and 25% – 35% in non-GAAP diluted EPS.
- The company credits this growth to four recently launched products in the U.S. and Europe that are expanding coverage and reimbursement.
- Executive comments highlight 11 growth catalysts, including new product and indication approvals as well as key reimbursement milestones.
- Halozyme announces a $250 million share buyback amidst its upward financial momentum.
- Analyst recommendations include 6 buys, 3 holds, and 0 sells.
Halozyme Therapeutics on Smartkarma
Analysts at Baptista Research have provided bullish coverage of Halozyme Therapeutics on Smartkarma. In their report titled “Halozyme Therapeutics: European Market Expansion to Capture The Oncology Treatment Market!”, they highlighted the company’s robust financial and operational performance in 2024. With total revenue exceeding $1 billion for the first time and a 22% increase over the previous year, Halozyme’s success was driven by a 27% growth in royalty revenue. The company’s high-margin royalty revenue was supported by the commercial success of key products like DARZALEX, Phesgo, and VYVGART Hytrulo for generalized myasthenia gravis.
In another report, “Halozyme Therapeutics Inc.: Intellectual Property Portfolio & Expansion Fueling Our ‘Outperform’ Rating! – Major Drivers”, Baptista Research continued their bullish sentiment on Halozyme. The company’s strong financial performance in the third quarter of 2024, marked by a 34% increase in total revenues to $290 million, was attributed to a 36% rise in royalty revenues, hitting $155 million. The growth was primarily fueled by the expanded adoption of the ENHANZE drug delivery technology, particularly through products like DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. Analysts believe that Halozyme’s intellectual property portfolio expansion is a key driver behind their ‘Outperform’ rating.
A look at Halozyme Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Halozyme Therapeutics, Inc. shows a promising future according to the Smartkarma Smart Scores. With a high Growth score of 4 and Momentum score of 5, the company appears to be on a strong trajectory for advancement in the long term. These scores suggest that Halozyme Therapeutics is well-positioned for growth and has positive momentum in the market.
Although the Value score is moderate at 2 and the Dividend score is low at 1, the company’s overall outlook seems optimistic. Additionally, with a Resilience score of 3, Halozyme Therapeutics demonstrates a certain level of stability in uncertain market conditions. Overall, based on its Smartkarma Smart Scores, Halozyme Therapeutics, Inc. is a biopharmaceutical company with a focus on product development in various key markets, showcasing significant potential for growth and success in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
